Compare · AKTS vs NVO
AKTS vs NVO
Side-by-side comparison of Aktis Oncology Inc. (AKTS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKTS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 145.1x AKTS ($1.48B).
- Over the past year, AKTS is up 20.8% and NVO is down 12.1% - AKTS leads by 32.9 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for AKTS).
- NVO has more recent analyst coverage (25 ratings vs 13 for AKTS).
- Company
- Aktis Oncology Inc.
- Novo Nordisk A/S
- Price
- $26.71+2.61%
- $48.65+3.65%
- Market cap
- $1.48B
- $215.46B
- 1M return
- +10.42%
- -2.08%
- 1Y return
- +20.81%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 5
- 9
- Recent ratings
- 13
- 25
Aktis Oncology Inc.
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AKTS
- Wedbush initiated coverage on Aktis Oncology with a new price target
- BMO Capital Markets initiated coverage on Aktis Oncology with a new price target
- SEC Form 10-Q filed by Aktis Oncology Inc.
- Aktis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
- Director Herrmann Ken exercised 4,856 shares at a strike of $0.59 and sold $119,274 worth of shares (4,856 units at $24.56) (SEC Form 4)
- Director Herrmann Ken exercised 3,065 shares at a strike of $0.08 and sold $77,259 worth of shares (3,065 units at $25.21) (SEC Form 4)
- Chief Operating Officer Ron-Bigger Shulamit exercised 50,000 shares at a strike of $3.66 and sold $1,387,558 worth of shares (50,000 units at $27.75) (SEC Form 4)
- Chief Medical Officer Czibere Akos exercised 50,000 shares at a strike of $4.95 and sold $1,388,701 worth of shares (50,000 units at $27.77) (SEC Form 4)
- Raymond James initiated coverage on Aktis Oncology with a new price target
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S